Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited (NASDAQ:HCM) delivers innovative oncology and immunology therapies through cutting-edge research and global clinical development. This news hub provides investors with timely updates on regulatory milestones, clinical trial progress, and strategic partnerships shaping the future of targeted cancer treatments.
Access official press releases covering drug approvals, financial results, and scientific breakthroughs alongside analysis of market-moving developments. Our curated collection includes updates on key therapies like fruquintinib (Elunate®) and sovleplenib, with insights into their commercial expansion across global markets.
Discover critical updates across three core areas: Clinical Development (Phase I-III trial results), Regulatory Strategy (FDA/EMA/NMPA interactions), and Commercial Operations (partnerships with Takeda, AstraZeneca). Bookmark this page for verified information directly from company filings and authorized communications.
HUTCHMED has initiated a Phase III clinical trial of HMPL-306 for relapsed/refractory acute myeloid leukemia (AML) patients with IDH1/IDH2 mutations in China. The trial, named RAPHAEL, started dosing the first patient on May 11, 2024. HMPL-306 is a dual-inhibitor targeting both IDH1 and IDH2 mutations, potentially overcoming resistance seen with single inhibitors. The trial aims to enroll around 320 patients and will compare HMPL-306's effectiveness and safety to current chemotherapy regimens. Key endpoints include overall survival, event-free survival, and complete remission rates. Previous Phase I data showed promising results, with more data expected in June 2024.
HUTCHMED announces the appointment of Dr. Renu Bhatia as an Independent Non-executive Director and member of the Technical Committee, bringing over 25 years of experience in healthcare, finance, fintech, and regulation. Dr. Bhatia's extensive expertise is expected to enhance the skill set and knowledge base of the Board. Her background includes roles in investment banking, asset management, venture capital, and compliance. The appointment is set to take effect on May 13, 2024.
FAQ
What is the current stock price of Hutchmed (China) (HCM)?
What is the market cap of Hutchmed (China) (HCM)?
